Kidney research and clinical practice · 2026
Ferric citrate for iron deficiency anemia in non-dialysis dependent chronic kidney disease: a randomized phase III study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Mei-Yi, Lee Chin-Chan, Lee Chien-Te, Tarng Der-Cherng, Chiang Chih-Kang, Chang Chiz-Tzung, Chiu Yi-Wen, Sue Yuh-Mou, Kao Chih-Chin, Peng Yu-Sen, Hung Cheng-Chieh, Wang Ming-Cheng, Wu Mai-Szu
Аннотация
BACKGROUND: Ferric citrate (FC) can replenish iron stores in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anemia (IDA). This study evaluated the efficacy and safety of FC (PBF-1681, Panion & BF Biotech Inc.) in NDD-CKD Taiwanese patients.
METHODS: In this double-blind, placebo-controlled, randomized Phase III trial, patients were assigned 1:1 to receive either PBF-1681 or placebo for 16 weeks, followed by an 8-week open-label extension in which all participants received PBF-1681. The starting dose was 2 g/day, with an additional 2 g/day titration based on hemoglobin and serum phosphate levels.
RESULTS: A total of 141 patients were randomized to either the PBF-1681 or placebo group. Of these, 114 completed the 16-week randomized period and 106 completed the full 24-week study. The primary endpoint was met, with the PBF-1681 group showing a significantly greater increase in hemoglobin from baseline to Week 16 compared to the placebo group (intergroup difference: 0.62 ± 0.15 g/dL, p < 0.0001). Significant between-group differences were also observed for all secondary and several exploratory endpoints, including the proportion with hemoglobin increase ≥1.0 g/dL, a sustained effect (hemoglobin increase of ≥0.75 g/dL from baseline over any 4-week time period), and changes in iron-related parameters, serum phosphate, intact parathyroid hormone, and fibroblast growth factor 23 levels (all p < 0.05). The most common treatment-related adverse events were gastrointestinal disorders, including diarrhea, discolored feces, abdominal discomfort, constipation, and abdominal pain.
CONCLUSION: PBF-1681 was effective for treating IDA in Taiwanese NDD-CKD patients and had a favorable safety profile.
METHODS: In this double-blind, placebo-controlled, randomized Phase III trial, patients were assigned 1:1 to receive either PBF-1681 or placebo for 16 weeks, followed by an 8-week open-label extension in which all participants received PBF-1681. The starting dose was 2 g/day, with an additional 2 g/day titration based on hemoglobin and serum phosphate levels.
RESULTS: A total of 141 patients were randomized to either the PBF-1681 or placebo group. Of these, 114 completed the 16-week randomized period and 106 completed the full 24-week study. The primary endpoint was met, with the PBF-1681 group showing a significantly greater increase in hemoglobin from baseline to Week 16 compared to the placebo group (intergroup difference: 0.62 ± 0.15 g/dL, p < 0.0001). Significant between-group differences were also observed for all secondary and several exploratory endpoints, including the proportion with hemoglobin increase ≥1.0 g/dL, a sustained effect (hemoglobin increase of ≥0.75 g/dL from baseline over any 4-week time period), and changes in iron-related parameters, serum phosphate, intact parathyroid hormone, and fibroblast growth factor 23 levels (all p < 0.05). The most common treatment-related adverse events were gastrointestinal disorders, including diarrhea, discolored feces, abdominal discomfort, constipation, and abdominal pain.
CONCLUSION: PBF-1681 was effective for treating IDA in Taiwanese NDD-CKD patients and had a favorable safety profile.